On Friday, Standard BioTools Inc (NASDAQ: LAB) was 7.81% up from the session before settling in for the closing price of $1.28. A 52-week range for LAB has been $0.92 – $2.25.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 11.61%. When this article was written, the company’s average yearly earnings per share was at 60.26%. With a float of $368.40 million, this company’s outstanding shares have now reached $383.61 million.
Standard BioTools Inc (LAB) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Standard BioTools Inc stocks. The insider ownership of Standard BioTools Inc is 4.20%, while institutional ownership is 74.11%. The most recent insider transaction that took place on Nov 20 ’25, was worth 586,260. In this transaction Director of this company bought 450,000 shares at a rate of $1.30, taking the stock ownership to the 64,050,000 shares. Before that another transaction happened on Nov 19 ’25, when Company’s Director bought 350,000 for $1.28, making the entire transaction worth $448,910. This insider now owns 63,600,000 shares in total.
Standard BioTools Inc (LAB) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.05 earnings per share (EPS) during the time that was less than consensus figure (set at -0.03) by -0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 60.26% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 42.89% during the next five years compared to 11.61% growth over the previous five years of trading.
Standard BioTools Inc (NASDAQ: LAB) Trading Performance Indicators
You can see what Standard BioTools Inc (LAB) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.14. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.12.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.34, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.12 in one year’s time.
Technical Analysis of Standard BioTools Inc (LAB)
Compared to the last year’s volume of 1.66 million, its volume of 1.79 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 83.21%.
During the past 100 days, Standard BioTools Inc’s (LAB) raw stochastic average was set at 64.69%, which indicates a significant decrease from 93.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0739 in the past 14 days, which was lower than the 0.0759 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2848, while its 200-day Moving Average is $1.2198. Nevertheless, the first resistance level for the watch stands at $1.4333 in the near term. At $1.4867, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.5733. If the price goes on to break the first support level at $1.2933, it is likely to go to the next support level at $1.2067. Now, if the price goes above the second support level, the third support stands at $1.1533.
Standard BioTools Inc (NASDAQ: LAB) Key Stats
There are 384,565K outstanding shares of the company, which has a market capitalization of 530.70 million. As of now, sales total 174,430 K while income totals -138,890 K. Its latest quarter income was 19,550 K while its last quarter net income were -34,690 K.
